Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$6.74
-0.3%
$6.76
$2.32
$14.84
$479.02M0.083.79 million shs1.66 million shs
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
$4.76
-23.1%
$6.70
$4.05
$12.75
$325.52M2.26582,125 shs6.41 million shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$11.53
-0.9%
$12.01
$8.51
$17.79
$660.28M2.02748,916 shs306,364 shs
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$7.22
+2.0%
$7.58
$4.26
$12.83
$515.28M0.9904,037 shs514,354 shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-8.15%+0.60%+10.10%+11.00%+180.50%
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-0.48%-3.88%-1.75%-10.03%+8.03%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-1.94%-2.35%-2.60%-29.34%-12.49%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
-0.42%+7.11%+4.89%-23.38%+38.82%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
1.8483 of 5 stars
3.41.00.00.02.02.50.0
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
2.3381 of 5 stars
3.52.00.00.02.01.70.6
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.1268 of 5 stars
3.51.00.00.01.93.30.0
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
2.5305 of 5 stars
0.03.00.00.02.60.83.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.86
Moderate Buy$18.80178.93% Upside
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
3.00
Buy$47.40895.80% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
3.00
Buy$27.00134.17% Upside
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/AN/AN/AN/A

Current Analyst Ratings

Latest SIGA, CMPS, ALT, and OLMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/24/2024
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
9/10/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$23.00 ➝ $23.00
9/9/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
8/23/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $120.00
8/22/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
8/12/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
8/9/2024
Altimmune, Inc. stock logo
ALT
Altimmune
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/8/2024
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$33.00 ➝ $31.00
8/7/2024
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/7/2024
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
8/2/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $48.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$409K1,171.19N/AN/A$2.75 per share2.45
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$3.65 per shareN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$4.61 per shareN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$172.96M2.98$1.03 per share7.02$2.77 per share2.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.62N/AN/AN/A-24,778.97%-53.09%-48.14%11/5/2024 (Estimated)
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$118.46M-$2.31N/AN/AN/AN/A-57.74%-47.90%10/31/2024 (Confirmed)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$96.65M-$2.07N/AN/AN/AN/A-44.18%-40.30%11/5/2024 (Estimated)
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$68.07M$1.176.175.78N/A48.55%51.40%39.58%11/5/2024 (Estimated)

Latest SIGA, CMPS, ALT, and OLMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/31/2024N/A
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$0.60N/A+$0.60N/AN/AN/A  
8/8/2024Q2 2024
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.34-$0.35-$0.01-$0.35N/A$0.01 million    
8/6/2024N/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.54-$0.54N/A-$0.54N/AN/A
8/1/2024Q2 2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$0.53-$0.56-$0.03-$0.56N/AN/A    
8/1/2024Q2 2024
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A$0.03+$0.03$0.03N/A$21.81 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
11.30
11.30
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
0.13
12.03
12.03
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/A
9.13
9.13
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A
8.26
5.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
46.19%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
55.40%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
4.25%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
19.40%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
1.54%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5071.07 million68.16 millionOptionable
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
12068.39 million65.48 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
8057.27 million46.16 millionOptionable
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
4071.37 million70.27 millionOptionable

SIGA, CMPS, ALT, and OLMA Headlines

Recent News About These Companies

(SIGA) Technical Pivots with Risk Controls

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
COMPASS Pathways logo

COMPASS Pathways

NASDAQ:CMPS
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Olema Pharmaceuticals logo

Olema Pharmaceuticals

NASDAQ:OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
SIGA Technologies logo

SIGA Technologies

NASDAQ:SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.